Nandrolone and Pitavastatin Interaction

Avoid
Mechanism-based 75% confidence

Nandrolone and Pitavastatin have a potentially harmful interaction with 75% confidence. Both Nandrolone and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Nandrolone

Anabolic-Androgenic Steroid | Joint & Collagen Support

Nandrolone binds to the androgen receptor (AR) with affinity comparable to testosterone, promoting nitrogen retention, protein synthesis, and satellite cell activation in skeletal muscle tissue. Its anabolic effects are mediated through AR-dependent gene transcription that upregulates muscle-specific proteins including myosin heavy chain and IGF-1.

Half-life: ~6-12 days (decanoate) Typical dose: 100-200 mg/week (therapeutic) anabolic, healing, sexual health
5 alpha reductaseandrogen receptorigf1progesterone receptor androgenicblood pressure raisingcarcinogenic riskcardiotoxic
View full profile

Pitavastatin

HMG-CoA Reductase Inhibitor | Low-Interaction Statin

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface.

Half-life: ~12 hours Typical dose: 1-4 mg/day cardiovascular
aromatase aromatase inhibitorhepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Blood Vessels
low
Liver
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Nandrolone, Pitavastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Nandrolone, Pitavastatin). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Nandrolone, Pitavastatin). Monitor accordingly.

Frequently Asked Questions

Can I take Nandrolone with Pitavastatin?

Combining Nandrolone with Pitavastatin is not recommended. Both Nandrolone and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Nandrolone and Pitavastatin safe together?

This combination carries significant risk. Both Nandrolone and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Nandrolone and Pitavastatin?

Both Nandrolone and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Nandrolone and Pitavastatin?

Nandrolone has a half-life of ~6-12 days (decanoate) and Pitavastatin has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Nandrolone vs Pitavastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.